StockMarketWire.com - Biotherapeutic product developer 4D pharma said it planned to raise at least £18m from a share placing to support ongoing clinical studies related to irritable bowl syndrome and oncology.
The funding would also enable the company to continue to fund its operations to at least two clinical study readout, as well as for general corporate purposes.
New 4D pharma shares were being offered at 50p each and the company said it had exercised a right to cause partner Merck to purchase $5m (£3.83m) of the shares.
'4D pharma is pleased to launch this funding round - its first since 2015 and in challenging market conditions for developers of new therapeutics - with strong support from existing and new investors, including our partner Merck and other US investors in addition to those in the UK,' chief executive Duncan Peyton said.
'This funding will enable us to reach important milestone data points in two clinical studies which we believe will represent material value inflection points as positive data, if generated, will provide strong further validation of our approach to developing live biotherapeutics.'
At 2:29pm: [LON:DDDD] 4d Pharma Plc Ord 0.25p share price was -10.5p at 58.75p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.